JP2008502584A5 - - Google Patents

Download PDF

Info

Publication number
JP2008502584A5
JP2008502584A5 JP2006534360A JP2006534360A JP2008502584A5 JP 2008502584 A5 JP2008502584 A5 JP 2008502584A5 JP 2006534360 A JP2006534360 A JP 2006534360A JP 2006534360 A JP2006534360 A JP 2006534360A JP 2008502584 A5 JP2008502584 A5 JP 2008502584A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
agent
monoclonal antibody
nucleolin
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008502584A (ja
Filing date
Publication date
Priority claimed from US10/683,480 external-priority patent/US7357928B2/en
Application filed filed Critical
Publication of JP2008502584A publication Critical patent/JP2008502584A/ja
Publication of JP2008502584A5 publication Critical patent/JP2008502584A5/ja
Pending legal-status Critical Current

Links

JP2006534360A 2003-10-09 2004-10-08 ヌクレオリンを抑制することによる悪性疾患の治療方法 Pending JP2008502584A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/683,480 US7357928B2 (en) 2002-04-08 2003-10-09 Method for the diagnosis and prognosis of malignant diseases
PCT/US2004/033174 WO2005035579A1 (en) 2003-10-09 2004-10-08 A method for the treatment of maligant diseases by inhibiting nucleolin

Publications (2)

Publication Number Publication Date
JP2008502584A JP2008502584A (ja) 2008-01-31
JP2008502584A5 true JP2008502584A5 (enExample) 2009-07-23

Family

ID=34435395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534360A Pending JP2008502584A (ja) 2003-10-09 2004-10-08 ヌクレオリンを抑制することによる悪性疾患の治療方法

Country Status (7)

Country Link
US (4) US7357928B2 (enExample)
EP (1) EP1687337B1 (enExample)
JP (1) JP2008502584A (enExample)
AU (1) AU2004279837B2 (enExample)
CA (1) CA2546730C (enExample)
ES (1) ES2473598T3 (enExample)
WO (1) WO2005035579A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7314926B1 (en) * 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
DE60331310D1 (de) * 2002-06-26 2010-04-01 Univ Louisville Res Found Verfahren zum apoptosenachweis
US7831293B2 (en) * 2005-05-10 2010-11-09 Advanced Clinical Solutions, Inc. Method of defining a biological target for treatment
CN1862258B (zh) * 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
US8481529B2 (en) 2006-05-16 2013-07-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
DE602007010459D1 (de) * 2007-09-04 2010-12-23 Inst Nat Sante Rech Med Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
US20090226914A1 (en) * 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
WO2009098464A2 (en) * 2008-02-05 2009-08-13 Antisoma Research Limited Biological materials and uses thereof
CA2724818C (en) 2008-05-22 2015-06-16 Centre National De La Recherche Scientifique (Cnrs) New optically pure compounds for improved therapeutic efficiency
CN102223896A (zh) * 2008-08-07 2011-10-19 西塞医疗中心 抗-β-2-微球蛋白试剂及其用途
KR100998365B1 (ko) * 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
US8737715B2 (en) * 2009-07-13 2014-05-27 H. Lee Moffitt Cancer And Research Institute, Inc. Methods and apparatus for diagnosis and/or prognosis of cancer
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
US10030045B2 (en) * 2010-02-19 2018-07-24 Ohio State Innovation Foundation Primers and methods for nucleic acid amplification
US9499860B2 (en) * 2010-02-19 2016-11-22 The Ohio State University Primers and methods for nucleic acid amplification
WO2011109677A2 (en) * 2010-03-04 2011-09-09 University Of Louisville Research Foundation, Inc. Methods of increasing macropinocytosis in cancer cells
EP2624849A2 (en) 2010-10-04 2013-08-14 Centre National de la Recherche Scientifique (C.N.R.S.) Multivalent synthetic compounds as antibiotic treatment
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
WO2013067268A1 (en) * 2011-11-03 2013-05-10 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
WO2014187856A1 (en) * 2013-05-21 2014-11-27 Deutsches Krebsforschungszentrum Nucleoli disorganisation by knocking down specific alu-repeat containing rna sequences
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
CN106405096A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备胃癌诊断试剂和治疗药物中的应用
CN106405084A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备肠癌诊断试剂和治疗药物中的应用
US11357849B2 (en) 2016-03-07 2022-06-14 Musc Foundation For Research Development Anti-nucleolin antibodies
US20170338925A1 (en) * 2016-05-20 2017-11-23 National Taiwan University Scheduling method of communication system using directional reference signals and related apparatuses using the same
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
EP3493852A1 (en) 2016-08-02 2019-06-12 University of Louisville Research Foundation, Inc. Targeted nanodroplet emulsions for treating cancer
US20200147230A1 (en) * 2017-03-20 2020-05-14 Cancer Therapeutics Laboratories, Inc. Tumor necrosis targeting compositions and methods
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
JP2022547224A (ja) 2019-09-10 2022-11-10 ユニヴァーシティー・オブ・ルイスヴィル・リサーチ・ファウンデイション・インコーポレーテッド ナノ粒子がコンジュゲートした抗ヌクレオリン剤・ｐｅｇ
CN114846029A (zh) * 2019-12-24 2022-08-02 迪哲(江苏)医药股份有限公司 新颖抗fgfr2b抗体
WO2021202425A1 (en) 2020-03-28 2021-10-07 University Of Louisville Research Foundation, Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent
JP2023526914A (ja) * 2020-05-07 2023-06-26 インターオリゴ・コーポレイション 新規核酸リガンド及びその識別方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192660A (en) * 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU635008B2 (en) * 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5736348A (en) * 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
JPH07242566A (ja) 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US6096532A (en) * 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
DE69636937T3 (de) 1995-12-15 2011-01-05 Virxsys Corp. Durch trans-spaltung erhaltene therapeutische molekule
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
EP1007669A1 (en) * 1997-03-12 2000-06-14 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
EP1003856A1 (en) * 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
AU6053898A (en) 1997-08-04 1999-02-22 Burnham Institute, The A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof
US6325785B1 (en) * 1997-08-14 2001-12-04 Sherwood Services Ag Sputum trap manifold with nested caps
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5932475A (en) * 1997-12-12 1999-08-03 Incyte Pharmaceuticals, Inc. Human nucleolin-like protein
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU762572B2 (en) 1998-04-10 2003-06-26 Chugai Seiyaku Kabushiki Kaisha Protein and gene involved in myocyte differentiation
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2000017648A1 (en) * 1998-09-24 2000-03-30 Promega Corporation Apoptosis marker antibodies and methods of use
US7314926B1 (en) 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
WO2000063250A1 (en) 1999-04-15 2000-10-26 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use
US6165786A (en) 1999-11-03 2000-12-26 Isis Pharmaceuticals, Inc. Antisense modulation of nucleolin expression
ES2288877T3 (es) 1999-11-08 2008-02-01 EISAI R&D MANAGEMENT CO., LTD. Metodo y reactivo para detectar la muerte celular.
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
WO2001091771A2 (en) 2000-06-01 2001-12-06 Theralife, Inc. Compositions for treating back and leg discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
AU6669401A (en) 2000-06-02 2001-12-11 Univ Connecticut Health Ct Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
DE10037861A1 (de) 2000-08-01 2002-02-14 Max Delbrueck Centrum Mittel zur Therapie maligner Erkrankungen
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
BR0211148A (pt) 2001-07-16 2004-06-29 Arla Foods Amba Processo para produção de tagatose
AU2002362436A1 (en) 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
WO2003087124A2 (en) 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
DE60331310D1 (de) 2002-06-26 2010-04-01 Univ Louisville Res Found Verfahren zum apoptosenachweis
TW200504210A (en) 2003-07-30 2005-02-01 Chin-Tarng Lin A nucleolin antisense inhibiting growth of cancer cell
US20050187176A1 (en) 2003-10-10 2005-08-25 Bates Paula J. Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases
CN1862258B (zh) 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法
US8540965B2 (en) 2005-07-29 2013-09-24 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
US20090226914A1 (en) 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
CN102573613B (zh) 2009-10-21 2015-07-29 健康研究有限公司 用于增强肿瘤显像的paa纳米粒子
US20110111002A1 (en) 2009-11-12 2011-05-12 Calin Viorel Pop Transport and delivery of glutathione into human cells using gold nanoparticles
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
WO2011119058A2 (en) 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
JP5244988B1 (ja) 2012-02-20 2013-07-24 浜松ホトニクス株式会社 濃度測定装置および濃度測定方法

Similar Documents

Publication Publication Date Title
CA2546730A1 (en) A method for the treatment of malignant diseases by inhibiting nucleolin
JP2025066807A (ja) 生体直交型組成物
Mjos et al. Metallodrugs in medicinal inorganic chemistry
JP2021120406A5 (ja) 癌を治療するための組み合わせ物
Tomek et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments
JP2021169479A5 (enExample)
JP2016522261A5 (enExample)
JP2020512314A5 (enExample)
JP2022523740A5 (enExample)
JP2013518912A5 (enExample)
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2019526578A5 (enExample)
IL195328A0 (en) Antibodies binding to anionic phospholipids and aminophospholipids and their use in the preparation of pharmaceutical compositions for treating viral infections
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
ATE472338T1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
WO2022093800A3 (en) Carrier particle-drug conjugates, self-immolative linkers, and uses thereof
CN108135901A (zh) 胆管癌的治疗
JP2004534741A5 (enExample)
JP2017514800A5 (enExample)
JP2009513662A5 (enExample)
JP2006507308A5 (enExample)
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
Cheng et al. Zeolitic imidazolate framework-8 encapsulating risedronate synergistically enhances osteogenic and antiresorptive properties for bone regeneration
JP2015514756A5 (enExample)